Placebo depot

DRUG2 trials

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.

Conditions

Schizophrenia

Phase 3

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

CompletedNCT00705783

Otsuka Pharmaceutical Development & Commercialization, Inc.Schizophrenia

Start: 2008-07-31End: 2011-02-28Updated: 2013-07-19

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

CompletedNCT00706654

Otsuka Pharmaceutical Development & Commercialization, Inc.Schizophrenia

Start: 2008-09-01End: 2012-08-01Updated: 2026-06-04

Related Papers

The effect of aripiprazole once-monthly on personal and social functioning: post hoc analyses of acute and long-term studies.

2019-06-245 citations

Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis.

2015-05-275 citations

Patient-Centered Outcomes with Aripiprazole Once-Monthly for Maintenance Treatment in Patients with Schizophrenia: Results From Two Multicenter, Randomized, Double-Blind Studies

Clinical Schizophrenia & Related Psychoses2015-02-2517 citations

Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study.

2014-06-12102 citations

EPA-0790 – All-cause discontinuation and safety of aripiprazole once-monthly for the treatment of schizophrenia: A pooled analysis of two double-blind, randomized, controlled trials

European Psychiatry2014-01-011 citations

EPA-0809 - Aripiprazole once-monthly for the treatment of schizophrenia in obese and non-obese patients; a post-hoc analysis

European Psychiatry2014-01-01

Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.

2012-05-01137 citations